Literature DB >> 32877795

Recurrence patterns after neoadjuvant chemoradiotherapy compared with surgery alone in oesophageal squamous cell carcinoma: results from the multicenter phase III trial NEOCRTEC5010.

Shiliang Liu1, Jing Wen2, Hong Yang3, Qiaoqiao Li1, Yuping Chen4, Chengchu Zhu5, Wentao Fang6, Zhentao Yu7, Weimin Mao8, Jiaqing Xiang9, Yongtao Han10, Lei Zhao1, Hui Liu1, Yonghong Hu1, Mengzhong Liu1, Jianhua Fu11, Mian Xi12.   

Abstract

BACKGROUND: The aim of this study was to compare recurrence patterns and prognostic factors for developing recurrences in patients with oesophageal squamous cell carcinoma (ESCC) who received neoadjuvant chemoradiotherapy (CRT) followed by surgery or surgery alone from a multicenter phase III trial NEOCRTEC5010. PATIENTS AND METHODS: Patients with locally advanced ESCC were randomly assigned in a 1:1 ratio to receive neoadjuvant CRT plus surgery (CRT + S group) or surgery alone (S group). CRT consisted of two cycles of vinorelbine and cisplatin with concurrent radiotherapy of 40.0 Gy in 20 fractions. Recurrence patterns, sites, frequency, and timing and potential prognostic factors were compared.
RESULTS: Of the 451 patients enrolled from 2007 to 2014, 411 patients who underwent resection were analysed. After a median follow-up of 51.9 months, 62 patients (33.7%) in the CRT + S group versus 104 patients (45.8%) in the S group experienced recurrences (P = 0.013). The CRT + S group demonstrated a significantly better locoregional failure-free survival (P = 0.012) and a more favourable distant metastasis-free survival (P = 0.028) than the S group. Recurrences occurred earlier in the S group (P = 0.053), and late relapses were much more frequent in the CRT + S group (P = 0.029). On multivariate analysis, R1 resection and surgery alone were adverse factors for developing locoregional recurrences, whereas R1 resection was the only independent factor associated with distant metastases.
CONCLUSIONS: The neoadjuvant CRT regimen was associated with significantly reduced locoregional and distant recurrences compared with surgery alone. Recurrence patterns, sites and frequency were different between groups. TRIAL REGISTRATION CLINICALTRIALS. GOV IDENTIFIER: NCT01216527.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Esophageal squamous cell carcinoma; Neoadjuvant chemoradiotherapy; Recurrence; Surgery; Survival

Year:  2020        PMID: 32877795     DOI: 10.1016/j.ejca.2020.08.002

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  9 in total

1.  Comparison of efficacy and safety between pembrolizumab combined with chemotherapy and simple chemotherapy in neoadjuvant therapy for esophageal squamous cell carcinoma.

Authors:  Zibin Liang; Xiaojian Li; Bingjiang Huang; Haiyan Shi; Xiaohua Gong; Jing Yu; Caixia Xiao; Bin Zhou
Journal:  J Gastrointest Oncol       Date:  2021-10

2.  Comparable Clinical Outcome Using Small or Large Gross Tumor Volume-to-Clinical Target Volume Margin Expansion in Neoadjuvant Chemoradiotherapy for Esophageal Squamous Cell Carcinoma.

Authors:  Tae Hoon Lee; Hak Jae Kim; Byoung Hyuck Kim; Chang Hyun Kang; Bhumsuk Keam; Hyeon Jong Moon; Yong Won Seong; Suzy Kim
Journal:  J Oncol       Date:  2022-06-03       Impact factor: 4.501

3.  Patterns and timing of recurrence in esophageal squamous cell carcinoma patients treated with neoadjuvant chemoradiotherapy plus esophagectomy.

Authors:  Yushi Nagaki; Satoru Motoyama; Yusuke Sato; Akiyuki Wakita; Hiromu Fujita; Yoshihiro Sasaki; Kazuhiro Imai; Yoshihiro Minamiya
Journal:  BMC Cancer       Date:  2021-11-09       Impact factor: 4.430

4.  Toripalimab Plus Paclitaxel and Carboplatin as Neoadjuvant Therapy in Locally Advanced Resectable Esophageal Squamous Cell Carcinoma.

Authors:  Wenwu He; Xuefeng Leng; Tianqin Mao; Xi Luo; Lingxiao Zhou; Jiaxin Yan; Lin Peng; Qiang Fang; Guangyuan Liu; Xing Wei; Kangning Wang; Chenghao Wang; Sha Zhang; Xudong Zhang; Xudong Shen; Depei Huang; Huan Yi; Ting Bei; Xueke She; Wenguang Xiao; Yongtao Han
Journal:  Oncologist       Date:  2022-02-03

Review 5.  Neoadjuvant Therapy for Locally Advanced Esophageal Cancers.

Authors:  Runkai Huang; Zhenbin Qiu; Chunwen Zheng; Ruijie Zeng; Wanxian Chen; Simeng Wang; Enmin Li; Yiwei Xu
Journal:  Front Oncol       Date:  2022-04-07       Impact factor: 5.738

6.  Neoadjuvant immune checkpoint inhibitor in combination with chemotherapy or chemoradiotherapy in resectable esophageal cancer: A systematic review and meta-analysis.

Authors:  He Wang; Sihan Li; Tingting Liu; Jun Chen; Jun Dang
Journal:  Front Immunol       Date:  2022-09-13       Impact factor: 8.786

Review 7.  Approach to Localized Squamous Cell Cancer of the Esophagus.

Authors:  Chloe Weidenbaum; Michael K Gibson
Journal:  Curr Treat Options Oncol       Date:  2022-08-31

8.  Multicenter, single-arm, phase II trial of camrelizumab and chemotherapy as neoadjuvant treatment for locally advanced esophageal squamous cell carcinoma.

Authors:  Jun Liu; Yang Yang; Zhichao Liu; Xiaolong Fu; Xiaoyue Cai; Hongxuan Li; Li Zhu; Yan Shen; Hong Zhang; Yifeng Sun; Hezhong Chen; Bentong Yu; Renquan Zhang; Jinchen Shao; Ming Zhang; Zhigang Li
Journal:  J Immunother Cancer       Date:  2022-03       Impact factor: 12.469

9.  Progression-Free Survival as Early Efficacy Endpoint in Resectable Esophageal Cancer Treated With Neoadjuvant Therapy: A Systematic Review.

Authors:  Jie Zhu; Jin Tao; Zhen Dai; Yan Tan; Li Jiang; Qifeng Wang; Jinyi Lang
Journal:  Front Oncol       Date:  2022-01-17       Impact factor: 6.244

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.